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Hyperfibrinolysis and Hypofibrinogenemia Diagnosed With
Rotational Thromboelastometry in Dogs Naturally Infected With
Angiostrongylus vasorum
N.E. Sigrist, N. Hofer-Inteeworn, R. Jud Schefer, C. Kuemmerle-Fraune, M. Schnyder, and
A.P.N. Kutter
Background: The pathomechanism of Angiostrongylus vasorum infection-associated bleeding diathesis in dogs is not fully
understood.
Objective: To describe rotational thromboelastometry (ROTEM) parameters in dogs naturally infected with A. vasorum
and to compare ROTEM parameters between infected dogs with and without clinical signs of bleeding.
Animals: A total of 21 dogs presented between 2013 and 2016.
Methods: Dogs with A. vasorum infection and ROTEM evaluation were retrospectively identiﬁed. Thrombocyte counts,
ROTEM parameters, clinical signs of bleeding, therapy, and survival to discharge were retrospectively retrieved from patient
records and compared between dogs with and without clinical signs of bleeding.
Results: Evaluation by ROTEM showed hyperﬁbrinolysis in 8 of 12 (67%; 95% CI, 40–86%) dogs with and 1 of 9 (11%;
95% CI, 2–44%) dogs without clinical signs of bleeding (P = .016). Hyperﬁbrinolysis was associated with severe hypoﬁbrino-
genemia in 6 of 10 (60%; 95% CI, 31–83%) of the cases. Hyperﬁbrinolysis decreased or resolved after treatment with 10–
80 mg/kg tranexamic acid. Fresh frozen plasma (range, 14–60 mL/kg) normalized follow-up ﬁbrinogen function ROTEM
(FIBTEM) maximal clot ﬁrmness in 6 of 8 dogs (75%; 95% CI, 41–93%). Survival to discharge was 67% (14/21 dogs; 95%
CI, 46–83%) and was not diﬀerent between dogs with and without clinical signs of bleeding (P = .379).
Conclusion and Clinical Importance: Hyperﬁbrinolysis and hypoﬁbrinogenemia were identiﬁed as an important pathome-
chanism in angiostrongylosis-associated bleeding in dogs. Hyperﬁbrinolysis and hypoﬁbrinogenemia were normalized by
treatment with tranexamic acid and plasma transfusions, respectively.
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Angiostrongylus vasorum infection in dogs is anemerging disease that has high morbidity and mor-
tality.1–3 The adult worm (13–21 mm) is a metas-
trongylid nematode that resides in the pulmonary
arteries and right heart in dogs and other wild canids.4–6
Infected dogs may exhibit clinical signs of verminous
pneumonia, coagulopathies, neurological deﬁciencies,
and pulmonary hypertension.7–13 Naturally infected
dogs may show clinical or internal signs of bleeding
with associated complications.1,3,9,11,13,14
Several studies have evaluated biochemical,
hematological, and coagulation proﬁles in dogs
both naturally and experimentally infected with
A. vasorum.7,8,10,11,13,15,16 Thrombocytopenia, decreased
factor V activity, and increased factor VIII activity were
identiﬁed during parasitic infection, and coagulation
abnormalities have been attributed mainly to dissemi-
nated intravascular coagulation (DIC).8,11,15,16 Deposits
of ﬁbrinogen within the pulmonary vessels further sug-
gest severe intravascular coagulation.7 However, the
exact pathomechanism of A. vasorum-associated bleed-
ing has not been elucidated. Plasmatic coagulation pro-
ﬁles and thrombocyte counts may be normal or
hypercoagulable despite clinical or radiographic signs of
bleeding in naturally infected dogs.11,17,18 Recently, low
ﬁbrinogen concentrations and diagnosis of hypocoagu-
lability based on thromboelastography (TEG) analysis
were identiﬁed.11 Hyperﬁbrinolysis has been suggested
as a possible pathomechanism in response to this publi-
cation,19 but was not described in the original study.11
Hyperﬁbrinolysis identiﬁed on TEG analysis is
described in a case report from a dog with A. vasorum
infection, but lysis was attributed to severe DIC rather
than to an independent pathomechanism.20
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Incidence, magnitude, and clinical relevance of hyper-
ﬁbrinolysis in dogs infected with A. vasorum have nei-
ther been systematically described in clinically or
experimentally infected dogs nor have they been com-
pared to clinical signs of bleeding in these patients.
Viscoelastic tests such as rotational thromboelastome-
try (ROTEM) measure the viscoelastic properties of
whole blood under low shear conditions and display the
changes in viscoelasticity in a graph.21 Several parame-
ters are automatically determined. The clotting time
(CT) describes the time until ﬁbrin formation starts.
The clot formation time (CFT) displays the kinetics of
clot formation and depends mainly on ﬁbrinogen con-
centration and thrombocyte numbers. The maximum
clot ﬁrmness (MCF) describes the maximal strength of
the ﬁbrin/thrombocyte clot in mm. Fibrinolysis can be
assessed by maximum lysis (ML) in % within 60 min-
utes of measurement.
Several coagulation activators are available from the
manufacturer. The EXTEM test investigates clot for-
mation by activation of the coagulation cascade
through proprietary tissue factor (extrinsic pathway),
whereas the INTEM test is activated by a contact acti-
vator (intrinsic pathway). In the APTEM test, ﬁbrinol-
ysis is inhibited by added aprotinin, an antiﬁbrinolytic,
to the EXTEM reagent. Comparison of the APTEM
to the EXTEM graph conﬁrms hyperﬁbrinolysis and
allows for diagnosis of hyperﬁbrinolysis in bleeding
human patients.23 The FIBTEM tracing enables deter-
mination of ﬁbrinogen concentrations by adding
cytochalasin D, a platelet inhibitor, to the EXTEM
reagent.21 The resultant MCF of the FIBTEM tracing
represents the functional ﬁbrinogen and correlates to
ﬁbrinogen concentrations determined by the Clauss
method.22
The ﬁrst aim of our retrospective study was to
describe EXTEM and FIBTEM parameters of dogs
naturally infected with A. vasorum. Secondly, we aimed
to compare ﬁndings, speciﬁcally presence of hyperﬁbri-
nolysis and hypoﬁbrinogenemia, between dogs with and
without clinical signs of bleeding. Additionally, treat-
ment of dogs with clinical signs of bleeding with fresh
frozen plasma (FFP) and tranexamic acid as an antiﬁb-
rinolytic drug is described and evaluated.
Our hypothesis was that EXTEM and FIBTEM
parameters would be diﬀerent between dogs with and
without clinical signs of bleeding and that hyperﬁbrinol-
ysis would normalize after treatment with tranexamic
acid.
Materials and Methods
The hospital database was searched for A. vasorum-positive
dogs that had at least 1 ROTEM analysis performed. Dogs were
included if they either had a positive fecal analysis result (A. vaso-
rum ﬁrst-stage larvae detected by the Baermann-Wetzel technique),
a positive serum antigen result by ELISA,24 a positive rapid in-
clinic assaya,25 conﬁrmation of A. vasorum infection at necropsy or
some combinations of these, and if they had a ROTEM analysis
performed at presentation. Dogs pretreated with fenbendazole or
moxidectin were excluded.
Patient records were searched for additional information includ-
ing signalment, presenting complaints, treatment before presenta-
tion, clinical signs at presentation including signs of respiratory
distress, respiratory rate, and presence or history of cough, or pul-
monary changes on thoracic radiographs. Thrombocyte numbers,
coagulation test results within 12 hours of presentation, and
ROTEM parameters during hospitalization were retrieved, as well
as diagnosis, therapy, duration of hospital stay, and survival to
discharge. The ROTEMb analysis was performed within 30 min-
utes of blood collection according to the manufacturer’s instruc-
tions with 3.2% citrated whole blood in a 1 : 9 ratio. Brieﬂy,
300 lL of 37.0° warm, citrated whole blood was incubated for
5 seconds with a single-portion EXTEM-Sc or FIBTEM-Sd
reagent, followed by transferring the incubated blood sample into
the ROTEM cuvettee and attaching the cuvette to the pin. An
automated pipette was used and samples were analyzed for
60 minutes. After measurement, all ROTEM tracings were visually
evaluated for artifacts. Of the parameters measured and calculated
by the ROTEM device, EXTEM CT, CFT, MCF, ML, and FIB-
TEM MCF were further evaluated in our patients. The FIBTEM
MCF was used as parameter representing functional whole-blood
ﬁbrinogen concentration.21 In some dogs, serum ﬁbrinogen con-
centration was measured by the Clauss method.
For statistical analysis, an undetectable FIBTEM MCF (green
line) was deﬁned as a FIBTEM MCF of 0 mm. An inﬁnite
EXTEM CFT due to the MCF not reaching 20 mm was deﬁned
as 3,600 seconds (60 minutes). Hyperﬁbrinolysis was deﬁned as the
ML at 60 minutes exceeding the in-house reference interval of 0–
10%.
Based on ROTEM results, dogs were classiﬁed as hypocoagula-
ble if ≥2 of the following parameters were abnormal compared to
the in-house reference intervals: prolonged CT or CFT, low
EXTEM or low FIBTEM MCF.
Statistical Analysis
Data were entered into a spreadsheet, and analyses were per-
formed by the statistical software program SPSSf. Distribution of
data was assessed by Shapiro-Wilk. Non-normally distributed con-
tinuous variables were analyzed with Mann-Whitney tests, and
normally distributed continuous variables were analyzed with
t-tests. The frequency distributions of the categorical or ordinal
(score) variables were derived. Conﬁdence intervals (CI) were cal-
culated based on the Wilson procedure without correction for con-
tinuity by an online calculator (http://www.vassarstats.net/prop1.
html). For comparison of coagulation parameters in dogs with
and without bleeding diathesis, the patient population was
grouped into dogs with and without clinical signs of bleeding at
admission. Associations between categorical variables were evalu-
ated by the chi-square test. When both variables were binary and
expected cell frequencies were <5, a 2-sided Fisher’s exact test was
used. A value of P < .05 was considered signiﬁcant.
Results
Thirty dogs with suspicion of A. vasorum infection
and ROTEM analysis were identiﬁed; 4 dogs were
excluded due to lack of a deﬁnitive diagnosis of A. va-
sorum infection and 5 were excluded because ROTEM
analysis was performed after initiation of anthelmintic
treatment, missing ROTEM analysis at presentation or
both. One dog that presented with clinical signs of
bleeding and that had ROTEM analysis performed 6 h
after PO fenbendazole administration was included.
Twenty-one dogs with a conﬁrmed diagnosis of
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A. vasorum infection and ROTEM analysis at presenta-
tion subsequently were evaluated; 6 dogs that were pre-
viously described13 were included in our study because
ROTEM parameters of these dogs had not been
described previously.
The cohort consisted of various breeds (Table S1); 3
dogs were Cavalier King Charles Spaniels (3/21,
14.3%), 2 were Chihuahuas (2/21, 9.5%), and the
remaining 16 dogs represented diﬀerent breeds. Median
age was 3.2 years (range, 0.6–10.3 years) and mean
weight was 18.6  13 kg (range, 2.8–42 kg); 9 of 21
dogs (43%) were male (6 intact, 3 castrated), and 12
dogs (57%) were female (7 intact, 5 spayed).
Dogs were presented with various complaints
(Table S1). Clinically visible bleeding was identiﬁed in
12 of 21 (57%) dogs at presentation; 9 of 21 dogs
(43%) presented with dyspnea, and 3 additional dogs
(14%) were panting at presentation. Coughing was
identiﬁed in 12 of 21 (57%) of the dogs, with 9 of 21
(43%) presenting with acute and 3 of 21 (14%) with
chronic cough. Radiographic signs compatible with par-
asitic bronchopneumonia26 could be identiﬁed on 19 of
20 (95%) thoracic radiographs; 5 of 21 (24%) dogs pre-
sented with neurological signs (Table S1).
Nine of 21 dogs (43%) showed hyperﬁbrinolysis on
the EXTEM tracing (Fig 1). Three additional dogs
showed a very slow rising and weak (<30 mm) MCF
(Table S2, Fig 2). Although 13 of 21 (62%) dogs pre-
sented with thrombocytopenia, only 2 (10%) had
thrombocyte counts that potentially may be associated
with spontaneous bleeding (2 dogs with thrombocyte
counts of 27,000/lL each).
Eight of 18 dogs (44%) that had FIBTEM performed
at presentation had a FIBTEM MCF of 0 mm. Overall,
10 of 20 (50%) dogs were hypoﬁbrinogenemic at pre-
sentation.
Comparison of ROTEM Parameters in Dogs With
and Without Clinical Signs of Bleeding
Twelve of 21 (57%; 95% CI, 37–76%) dogs presented
with various clinical signs of bleeding. The 2 groups
were comparable in terms of median age (4.9 years;
range, 0.9–10.3 years and 1.9 years; range, 0.6–
9.8 years; P = .148) and median weight (5.1 kg; range,
2.8–35.0 kg and 21.4 kg; range, 0.6–42 kg; P = .058).
The nonbleeding group included 5 of 9 (56%) male and
4 of 9 (44%) female dogs whereas the group with clini-
cal signs of bleeding consisted of 4 of 12 (33%) male
and 8 of 12 (67%) female dogs (P = .185). Hospitaliza-
tion time was 2.5 days (range, 0.5–11 days) in non-
bleeding dogs vs 4.5 days (range, 0.5–8 days) in dogs
with clinical signs of bleeding (P = .310). Presence of
dyspnea at presentation (P = .595) and history of
coughing (P = .757) were similar in both groups
(Table 1).
The ROTEM abnormalities in dogs with and without
clinical signs of bleeding diathesis are summarized in
Tables 1 and 2. The ROTEM evaluation showed
hypocoagulability in 11 of 12 (92%; 95% CI, 65–99%)
dogs with clinical signs of bleeding and was signiﬁcantly
diﬀerent from nonbleeding dogs (P = .002); (Table 1).
Presence of thrombocytopenia (P = .397) and median
thrombocyte numbers (P = .370) were not signiﬁcantly
diﬀerent between dogs with and without clinical signs
of bleeding (Tables 1 and 2).
Eight of the 12 dogs with clinical signs of bleeding
showed hyperﬁbrinolysis on the EXTEM tracing, corre-
sponding to a 67% (95% CI, 40–86%) incidence of
hyperﬁbrinolysis (ML range, 62–100%) in bleeding
dogs. In contrast, only 1 of 9 (11%; 95% CI, 2–44%)
of the nonbleeding dogs showed increased lysis (ML
12%); (Table 1, P = .016).
The FIBTEM MCF at presentation was signiﬁcantly
lower in dogs with clinical signs of bleeding compared
to dogs without bleeding (P = <.001); (Table 2). A FIB-
TEM MCF of 0 mm or serum ﬁbrinogen concentration
Fig 1. EXTEM tracing of a dog with clinical signs of bleeding
and hyperﬁbrinolysis before (A) and after (B) treatment with
tranexamic acid. C shows a normal rotational thromboelastometry
(ROTEM) tracing of a dog with Angiostrongylus vasorum infection
without clinical signs of bleeding.
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<1 g/L was identiﬁed at presentation in 10 of 11 dogs
(91%; 95% CI, 62–98%) with clinical bleeding diatheses
but in none of the dogs without clinical signs of bleed-
ing (P = <.001, Table 1). All 6 hyperﬁbrinolytic dogs in
the bleeding group that had FIBTEM performed at pre-
sentation showed concurrent hypoﬁbrinogenemia.
Hypoﬁbrinogenemia was signiﬁcantly associated with
hyperﬁbrinolysis (P = .010).
A total of 12 of 21 (57%; 95% CI, 37–76%) dogs
had repeated ROTEM analysis performed after initia-
tion of therapy (Table S2). As only 3 dogs in the group
without clinical signs of bleeding had repeat ROTEM
results, follow-up ROTEM parameters were not evalu-
ated statistically.
Treatment
All dogs were treated with fenbendazole or mox-
idectin and prednisolone and additional symptomatic
medications as deemed necessary by the clinician in
charge; 1 dog treated with fenbendazole (50 mg/kg)
6 hours before ROTEM analysis was included in the
study because fenbendazole is not expected to have a
clinically relevant anthelmintic eﬀect within 6 h.27
One dog (11%; 95% CI, 2–44%) without and 9 of 12
(75%; 95% CI, 47–91%) with clinical signs of bleeding
received FFP (Table 3). A median dose of 29 mL/kg
(range, 14–60 mL/kg) was administered; 8 dogs with
clinical signs of bleeding and concurrent hypoﬁbrino-
genemia received FFP, which normalized follow-up
FIBTEM MCF in 6 of 8 dogs (75%; 95% CI, 41–
93%). However, 4 of the 6 dogs required >1 FFP trans-
fusion for normalization of FIBTEM MCF (Table S2).
Twelve of 21 dogs (57%; 95% CI, 37–76%) were
treated with tranexamic acidg, including 2 of 9 (22%;
95% CI, 6–55%) dogs without and 10 of 12 (83%; 95%
CI, 55–95%) dogs with clinical signs of bleeding diathe-
sis (P = .002). Tranexamic acid was administered as a
10–20 mg/kg bolus over 15–20 minutes and was
repeated after 6–8 hours or sooner if indicated by fol-
low-up EXTEM evaluation. Maximum lysis decreased
in all 7 hyperﬁbrinolytic dogs treated with tranexamic
acid (Table 3, Fig 1); 2 dogs with hyperﬁbrinolysis (100
and 99%, respectively) required >20 mg/kg tranexamic
acid because this dose decreased EXTEM ML only to
72 and 77%, respectively. Hyperﬁbrinolysis resolved on
day 1 in 1 of these dogs, whereas the other died (pro-
gression to status epilepticus) before an additional
EXTEM could be performed. Two other dogs with
hyperﬁbrinolysis did not receive tranexamic acid
because hyperﬁbrinolysis was not correctly identiﬁed at
the time of ROTEM analysis; 1 was euthanized and the
other died within 8 hours after admission, both as a
consequence of severe, progressive neurological signs.
Fourteen of 21 dogs survived to discharge (67%;
95% CI, 46–83%) which was not signiﬁcantly diﬀerent
Fig 2. EXTEM tracings of 2 dogs with Angiostrongylus vasorum
infection and clinical signs of bleeding. A shows a severely pro-
longed clot formation time and a low maximum clot ﬁrmness that
does not reach maximal amplitude at 60 minutes, B additionally
shows hyperﬁbrinolysis.
Table 1. Frequencies of clinical signs, thrombocyte number, and rotational thromboelastometry (ROTEM) parame-
ters at presentation in dogs with Angiostrongylus vasorum infection with (bleeding dogs) and without (nonbleeding
dogs) clinical signs of bleeding diathesis.
Parameter at presentation
Nonbleeding dogs (n = 9) Bleeding dogs (n = 12)
P-valuen/N % 95% CI n/N % 95% CI
Dyspnoea 5/9 55.6 27–81 4/12 33.3 14–61 .595
History of coughing 6/9 67 35–88 6/12 50.0 25–75 .379
Thrombocytopenia 5/9 55.6 27–81 9/12 75.0 47–91 .397
EXTEM lysis (maximum lysis >10%) 1/9 11 2–44 8/12 67 39–86 .016
Low ﬁbrinogena 0/9 0 0–3 10/11 91 62–98 <.001
Lysis in combination with low FIBTEM 0/9 0 0–3 7/11 64 35–85 .004
ROTEM hypocoagulable 2/9 22 6–55 11/12 92 65–99 .002
aLow ﬁbrinogen, deﬁned as FIBTEM MCF<3 mm or ﬁbrinogen measured by Clauss <1.0 g/L.
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between dogs with and without clinical signs of bleeding
at presentation (Table 1, P = .379); 6 of 7 dogs with a
diagnosis of hyperﬁbrinolysis that were treated with
tranexamic acid survived to discharge.
Discussion
Ours is the ﬁrst study to systematically describe
hyperﬁbrinolysis and its treatment with tranexamic acid
in dogs naturally infected with A. vasorum. Distinct
hyperﬁbrinolysis was identiﬁed in 67% of the dogs with
clinical signs of bleeding whereas only 1 dog without
clinical signs of bleeding showed hyperﬁbrinolysis. We
therefore suspect hyperﬁbrinolysis to be a major under-
lying pathomechanism in dogs with bleeding diathesis
as a consequence of A. vasorum infection.
Hyperﬁbrinolysis has been reported in humans with
various diseases, including trauma,28–30 and is a reason
for severe uncontrollable clinical bleeding.29,31 It has
been documented previously in a dog with A. vasorum
infection,20 a dog with acute traumatic coagulopathy32
and in dogs with spontaneous hemoperitoneum.33
Hyperﬁbrinolysis may develop independently of activa-
tion of the coagulation cascade and occurs when plas-
min generation exceeds the neutralizing capacity of
antiplasmins.34 Hyperﬁbrinolysis leads to rapid degra-
dation of cross-linked ﬁbrin and possibly to overt bleed-
ing diathesis. The degradation of ﬁbrin and cross-linked
ﬁbrin leads to increased concentrations of ﬁbrinogen
degradation products (FDPs) and D-dimers.34 Fibrino-
gen degradation products were not measured in our
study, and D-Dimer concentrations were determined in
only 3 dogs (data not shown).
The factors leading to induction of hyperﬁbrinolysis
in A. vasorum infection remain to be determined.
Hyperﬁbrinolysis may result from depletion of plas-
minogen activator inhibitor 1 by increased concentra-
tions of activated protein C, the latter being excessively
produced by thrombomodulin upregulation.30 Throm-
bomodulin upregulation has been associated with
hypoperfusion in human trauma patients,30 and hyper-
lactatemia has been associated with hyperﬁbrinolysis in
dogs with spontaneous hemoperitoneum33 and in
humans with trauma.28,30 Hyperﬁbrinolysis may further
be induced by endothelial plasminogen activator
released after endothelial trauma.35 Impairment of host
coagulation also has been reported in Diroﬁlaria immitis
infections. Diroﬁlaria immitis-derived antigens have
been shown to activate ﬁbrinolysis by binding to plas-
minogen and leading to generation of plasmin, but also
by enhancing plasminogen activators.36,37 Adult A. va-
sorum worms and ﬁrst-stage larvae or their metabolic
products also may lead to mechanical or chemical
injury of endothelial cells in the right ventricle and pul-
monary arteries with subsequent release of plasminogen
activator. They also may directly release a plasminogen
Table 2. Hematocrit (Hct), thrombocyte count, and ROTEM parameters at presentation in dogs with Angiostrongy-
lus vasorum infection with (bleeding dogs) and without (nonbleeding dogs) clinical signs of bleeding diathesis.
Parameter Reverence interval
Nonbleeding dogs (n = 9) Bleeding dogs (n = 12)
P-valuen
Median
Mean  SD Range (min–max) n
Median
Mean  SD Range (min–max)
Hct (%) 40–55 9 44  8.5 31–60 11 34.4  14.1 18–67 .077
Thrombocytes (106/lL) 130–394 9 109 27–299 11 87 27–279 .370
EXTEM CT (s) 26–57 9 37  11 27–56 12 189  89 41–388 <.001
EXTEM CFT (s) 53–153 9 182  141 63–520 12 1,465  1,349 165–3,600 <.001
EXTEM a-angle (°) 62–82 9 70 57–82 12 27.5 9–59 <.001
EXTEM MCF (mm) 46–62 9 55 30–71 12 28 14–57 <.001
EXTEM ML (%) 0–10 9 2 0–12 12 61 0–100 .015
FIBTEM MCF (mm) 3–9 9 12 3–16 9 0 0–8 <.001
CFT, clot formation time; CT, clotting time; ML, maximum lysis; ROTEM, rotational thromboelastometry.
Table 3. Treatment and outcome of 21 dogs with Angiostrongylus vasorum infection with (bleeding dogs) and with-
out (nonbleeding dogs) clinical signs of bleeding diathesis.
Parameter
Nonbleeding dogs (n = 9) Bleeding dogs (n = 12)
P-valuen/N % 95% CI n/N % 95% CI
FFP administration 1/9 11 2–44 9/12 75 47–91 .008
FFP for low ﬁbrinogen 0/9 0 0–30 8/11 73 43–90 .001
Normalization of ﬁbrinogen after FFP 0/1 0 0–80 6/8 75 41–93 .533
TXA administration 2/9 22 6–55 10/12 83 55–95 .008
TXA for hyperﬁbrinolysis 1/9 11 2–44 6/12 50 25–75 .078
Decreased hyperﬁbrinolysis after TXA 1/1 100 21–100 6/6 100 61–100 NA
Survival to discharge 5/9 55.6 27–81 9/12 75.0 47–91 .379
FFP, fresh frozen plasma; TXA, tranexamic acid; CI, conﬁdence interval; NA, not assessed.
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activator, as described for D. immitis.36–38 A high per-
centage of A. vasorum-infected dogs show classical
radiographic signs of verminous bronchopneumonia
and suspicion of pulmonary bleeding.26,39 Several of
our dogs that initially presented with hemoptysis but
without dyspnea showed worsening of pulmonary func-
tion and severe postmortem evidence of pulmonary
bleeding. These ﬁndings support the hypothesis that the
pathogen itself directly contributes to coagulopathy pri-
marily in the pulmonary vessels with or without concur-
rent systemic activation of the coagulation cascade.
Hyperﬁbrinolysis as a pathomechanism for bleeding
diathesis in our dogs with A. vasorum infection is
supported by the concurrent presence of severe
hypoﬁbrinogenemia.19 Most dogs with hyperﬁbrinolysis
had a nondetectable FIBTEM MCF (green line)
whereas none of the dogs without clinical signs of
bleeding diathesis showed evidence of hypoﬁbrinogene-
mia. We suspect hypoﬁbrinogenemia to be a sign of
increased loss of ﬁbrinogen as a result of severe hyper-
ﬁbrinolysis, resulting from increased consumption due
to continuous clot lysis.40 Blood loss as a cause for
hypoﬁbrinogenemia seems less likely because the hemat-
ocrit and thrombocyte numbers would be expected to
be substantially decreased, which was not the case in
our dogs. Fibrinogen, an acute-phase protein produced
during the inﬂammatory stages of the disease, was
decreased in many of our dogs. Hyperﬁbrinogenemia as
a sequel of the inﬂammatory reaction to adult worms,
larvae, or their metabolic products would be expected
in dogs with A. vasorum infection.7 Disseminated
intravascular coagulation has been suspected as the
main pathomechanism leading to bleeding diathesis in
previous studies and may be associated with both
hyperﬁbrinolysis and hypoﬁbrinogenemia.1,8,11,15,16,20
We cannot completely rule out DIC as the reason for
distinct hyperﬁbrinolysis and hypoﬁbrinogenemia
because increased ﬁbrinolytic activity has been stated to
be a feature of DIC.41 However, studies showing hyper-
ﬁbrinolysis in dogs with suspected DIC are lacking and
a recent study of humans did not identify hyperﬁbrinol-
ysis and hypoﬁbrinogenemia (indicated by low FIB-
TEM MCF) in patients with DIC.42 Furthermore, dogs
with DIC rarely show very low ﬁbrinogen concentra-
tions.17,43 Additionally, previous studies in naturally
infected dogs reported plasmatic coagulation proﬁles
and thrombocyte counts to be normal despite clinical or
radiographic signs of bleeding.11,17,18 A diﬀerent, previ-
ously undetected pathomechanism leading to bleeding
diathesis in A. vasorum infection therefore is expected.
Based on our ﬁndings, hyperﬁbrinolysis and associated
hypoﬁbrinogenemia seem to be important pathomecha-
nisms of bleeding diathesis and are induced by the
parasite itself rather than being a consequence of DIC.
Other pathomechanisms for bleeding diathesis have
been discussed. Thrombocytopenia alone does not
explain the bleeding diathesis because several dogs with
clinical bleeding had normal thrombocyte numbers.11
This ﬁnding is in agreement with those of our study in
which median thrombocyte counts were not diﬀerent
between dogs with and without clinical signs of
bleeding. Thrombocytopathia has been suggested as a
cause for bleeding because both thrombocyte numbers
and secondary coagulation parameters can be normal.11
To our knowledge, thrombocytopathia has not speciﬁ-
cally been investigated so far and should be included in
future studies.
The identiﬁcation of hyperﬁbrinolysis as a main path-
omechanism for A. vasorum-associated bleeding diathe-
sis oﬀers a new treatment modality. Treatment of
hyperﬁbrinolysis with tranexamic acid as an antiﬁbri-
nolytic drug has become common practice in human
trauma patients and surgery-related bleeding and has
led to a substantial decrease in the use of blood
products.44,45 Tranexamic acid is a readily available
antiﬁbrinolytic agent that competitively binds to lysine-
binding sites on plasminogen and plasmin, therefore
interfering with the formation of plasmin from its pre-
cursor plasminogen.46,47 Although hyperﬁbrinolysis in
A. vasorum infection has been described in a dog,20 our
study is the ﬁrst to describe treatment of A. vasorum-
induced bleeding with tranexamic acid. All but 2 dogs
with hyperﬁbrinolysis were treated with tranexamic acid
immediately after identiﬁcation of hyperﬁbrinolysis.
Our results indicate that hyperﬁbrinolysis decreased or
normalized after treatment with tranexamic acid. The
dosage of tranexamic acid required to normalize hyper-
ﬁbrinolysis in our study was derived empirically from
data in humans and own clinical experience with
repeated monitoring of hyperﬁbrinolytic patients. The
dosage remains speculative because no pharmacological
studies evaluating the minimal required dosage to inhi-
bit hyperﬁbrinolysis have been performed. In a study
using an in vitro model of hyperﬁbrinolysis induced by
tissue plasminogen activator, dosages up to 10 times
those used in humans were suggested to be necessary to
inhibit induced hyperﬁbrinolysis in dogs.48 Our dogs
received dosages of 10–20 mg/kg q6–8h, which
decreased hyperﬁbrinolysis in all dogs. However, several
dogs needed repeated doses of tranexamic acid (up to
80 mg/kg) until ﬁbrinolysis normalized. Although most
dogs treated with tranexamic acid for hyperﬁbrinolysis
also received FFP as treatment for severe concurrent
hypoﬁbrinogenemia, FFP itself is not expected to inhi-
bit hyperﬁbrinolysis. In the previously mentioned case
report describing a dog with A. vasorum infection and
hyperﬁbrinolysis, treatment with antiparasitic drugs and
FFP did not resolve hyperﬁbrinolysis completely.20 We
therefore conclude that tranexamic acid was successful
in treating dogs with hyperﬁbrinolysis and bleeding
diathesis. All dogs that reached normal ML after treat-
ment of hyperﬁbrinolysis survived to discharge.
Hypoﬁbrinogenemia in our dogs was treated success-
fully with FFP transfusions. As described in the human
medical literature, large amounts of FFP (mean,
29 mL/kg; range, 14–60 mL/kg) were required to
increase FIBTEM MCF’s into the lower end of the ref-
erence interval.49–51
An interesting ﬁnding was the very low EXTEM
MCF that was combined with slow clot formation in
3 dogs without evident hyperﬁbrinolysis (Fig 2).
The low EXTEM MCF may be a sign of
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thrombocytopathia.11,19 However, because all 3 dogs
had substantial improvement in CFT and EXTEM
MCF after therapy with tranexamic acid and FFP, we
suspect that concurrent clot lysis during clot formation
without evident hyperﬁbrinolysis caused the weak clot.
The ROTEM evaluation identiﬁed 91% of the clini-
cally bleeding dogs as being hypocoagulable. By TEG,
94% of bleeding dogs were identiﬁed as being hypoco-
agulable.11 We deﬁned the group of bleeding dogs based
on clinically visible signs of bleeding, and patients with
suspicion of internal bleeding (pulmonary or intracra-
nial) were not included in this group. Therefore, we
believe that the results are comparable and that vis-
coelastic tests are suitable for the identiﬁcation of
hypocoagulability in A. vasorum-infected dogs.
Being retrospective in nature, our study has several
limitations. The ROTEMs were not repeated at stan-
dardized timepoints, with some dogs having only 1
measurement available. In addition, treatment was not
standardized, and therefore, conclusions regarding treat-
ment eﬀects are limited. Furthermore, hyperﬁbrinolysis
identiﬁed on ROTEM tracings was not compared to
APTEM tracings. Because all EXTEM tracings with
hyperﬁbrinolysis improved or normalized after treat-
ment of dogs with tranexamic acid, this in vivo antiﬁb-
rinolytic treatment indicates the initial presence of
hyperﬁbrinolysis. Furthermore, distinct hyperﬁbrinolysis
as seen in our dogs with A. vasorum infection is a rare
ﬁnding in EXTEM tracings in our hospitalized dogs
with other diseases (data not shown) and is not com-
monly identiﬁed on standard ROTEM analysis.51
Survival after treatment was 67% and not diﬀerent
between dogs with and without clinical signs of bleeding
at presentation; 2 of the dogs with severe hyperﬁbrinoly-
sis were not treated with tranexamic acid, because hyper-
ﬁbrinolysis was not recognized at the time, and both
dogs died. In 5 of 12 dogs, treatment with tranexamic
acid was initiated without signs of bleeding or diagnosis
of hypocoagulable state or hyperﬁbrinolysis. Doing so
might be detrimental in cases that are in a hypercoagula-
ble state even though tranexamic acid has not been asso-
ciated with severe adverse eﬀects.46,52 On the other hand,
2 dogs with normal ROTEM parameters and no clinical
signs of bleeding at presentation developed severe pul-
monary bleeding during hospitalization, leading to
death. Prophylactic treatment of hyperﬁbrinolysis in
these dogs may have prevented death.
Although hyperﬁbrinolysis seems to be an important
pathomechanism in A. vasorum-associated bleeding
diathesis, several questions still remain. A prospective,
randomized study with a larger population of dogs in
various stages of infection is required to fully address
the complete pathomechanism of A. vasorum-associated
bleeding and to evaluate whether treatment of hyperﬁb-
rinolysis with tranexamic acid alone may be suﬃcient to
decrease bleeding diathesis.
Conclusion
We identiﬁed hyperﬁbrinolysis and severe hypoﬁb-
rinogenemia associated with clinical signs of
hemorrhage in dogs naturally infected with A. vasorum.
Hyperﬁbrinolysis and hypoﬁbrinogenemia were treated
successfully with tranexamic acid and FFP transfusions,
respectively. A prospective clinical trial with consistent
diagnostic evaluation and treatment protocols is war-
ranted.
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